Edouard Larrey
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 24, 2026
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study.
Journal: JHEP reports : innovation in hepatology
Published: July 11, 2024
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: December 01, 2023
Enhanced therapeutic outcomes with atezolizumab-bevacizumab and SIRT combination compared to SIRT alone in unresectable HCC: A promising approach for improved survival.
Journal: Clinics and research in hepatology and gastroenterology
Published: November 21, 2023
Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
Journal: Clinics and research in hepatology and gastroenterology
Published: August 08, 2023
Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma.
Journal: Alimentary pharmacology & therapeutics
Published: March 12, 2023
Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: September 09, 2022
A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: June 03, 2022
A standardized immunosuppressive regimen for patients who received liver transplantations treated with atezolizumab-bevacizumab to avoid graft rejection?
Journal: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Published: February 21, 2022
"De novo" cholangiocarcinoma 20 years after liver transplantation for primary sclerosing cholangitis: Lifelong screening needed!
Journal: Clinics and research in hepatology and gastroenterology
Published: July 08, 2021
Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage à trois" !
Journal: Clinics and research in hepatology and gastroenterology
Published: June 21, 2021
Last Updated: 09/26/2026